Duality Biologics Agrees to BeiGene Preclinical Asset Purchase

Following shortly after signing a contract with BioNTech, Duality Biologics has agreed to a preclinical asset purchase with BeiGene in exchange for up to $1.3 billion.

Back in April, BioNTech invested $170 million for the licences of HER2 targeted biopharmaceuticals, one to challenge an existing AstraZeneca candidate.

DualityBio has designed their drug line with the intention of being the finest available on the market. And now they have found another company excited to purchase in one of their candidates.

Although the exact number has not been made public, we know that BeiGene is fronting part of the finance to secure exclusive international rights to experimental preclinical targeted treatment for individuals with solid tumours.

If BeiGene chooses to purchase the drug, DualityBio will be eligible to collect milestone payments for growth, legal, and commercial success. This may bring the total value of the agreement to $1.3 billion.

BeiGene’s Research & Development Lead, Lai Wang, explained how the collaboration leaves them “well positioned to advance this asset globally alongside our initial internally discovered ADC assets with our end-to-end ADC manufacturing capabilities.”

The aim of DualityBio and BeiGene’s collaborative venture is still being kept under wraps. DualityBio’s efforts to increase the potential of ADC’s has involved the employment of various technologies to enhance durability and reduce disruptive reactions.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.